CBD Life Sciences, Inc. (CBDL) Signs MOU With Large Mushroom Supplement Company
SCOTTSDALE, AZ / ACCESSWIRE / August 1, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), including its wholly-owned subsidiary, The...
Day: August 1, 2024
RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of...
RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of...
FDA Recognizes Fibromyalgia as a ‘Serious Condition’ And Fast-Tracks New Drug Candidate
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding...
FDA Recognizes Fibromyalgia as a ‘Serious Condition’ And Fast-Tracks New Drug Candidate
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding...
Bausch Health Announces Second Quarter 2024 Results
Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basisConsolidated GAAP...
Bausch Health Announces Second Quarter 2024 Results
Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basisConsolidated GAAP...
OMS360 Appoints Dr. Joshua Everts as Chief Clinical Officer
ATLANTA, GA / ACCESSWIRE / August 1, 2024 / OMS360 has appointed Joshua Everts, DDS, MD, a distinguished oral and...
OMS360 Appoints Dr. Joshua Everts as Chief Clinical Officer
ATLANTA, GA / ACCESSWIRE / August 1, 2024 / OMS360 has appointed Joshua Everts, DDS, MD, a distinguished oral and...
Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of...
Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of...
Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates
Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33)Updates 2024 financial...
Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates
Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33)Updates 2024 financial...
Zomedica to Report Second Quarter 2024 Financial Results and Provide Business Update on August 14 at 4:30 p.m. ET
ANN ARBOR, MI / ACCESSWIRE / August 1, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary...
Zomedica to Report Second Quarter 2024 Financial Results and Provide Business Update on August 14 at 4:30 p.m. ET
ANN ARBOR, MI / ACCESSWIRE / August 1, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary...
“NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy”; “Novel Anti-Viral Could Boost a US$3 Billion Market” – Conclude Two Independent Research Reports on NanoViricides
SHELTON, CT / ACCESSWIRE / August 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader...
Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System
The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous systemBRAINTREE, Mass.,...
Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024
MIAMI, FL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024
CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on...
Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET
AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s...